MedTrace Logo

Erwinase Master Treatment Protocol

NCT00590915 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-01-23

No results posted yet for this study

Summary

The purpose of this study is to make Erwinase available to patients with acute lymphoblastic leukemia (ALL) who have had previous allergic reactions to certain formulations of L-asparaginase.

Conditions

  • Leukemia, Acute Lymphoblastic
  • Acute Lymphoid Leukemia

Interventions

DRUG

Erwinia L-asparaginase

Substitute Erwinia L-asparaginase 25,000 international units per meters squared, IM every other day (including weekends and holidays) x 6 doses for each dose of PEG-asparaginase that is replaced. NOTE: Erwinia L-asparaginase dosing to replace native E.coli L-asparaginase varies; consult protocol for specifics.

Sponsors & Collaborators

  • Fisher Bioservices

    collaborator INDUSTRY

  • Jazz Pharmaceuticals

    collaborator INDUSTRY

  • Phoenix Children's Hospital

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00590915 on ClinicalTrials.gov